1. ACADIA pharmaceuticals presents positive top-line results from pivotal phase 3 harmony trial of pimavanserin in patients with dementia-related psychosis at 12th clinical trials on Alzheimer’s Disease (CTAD) Meeting,2019
2. Challenging behaviors: common questions,2013
3. Alzheimer’s Will be a Global Epidemic by 2050,2013
4. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study;Ballard;Lancet Neurol.,2018
5. A 52-week open-label extension study of pimavanserin for the treatment of agitation and aggression in subjects with Alzheimer’s Disease,2019